908 related articles for article (PubMed ID: 23831265)
1. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
2. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response.
Pawar D; Jaganathan KS
Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494
[TBL] [Abstract][Full Text] [Related]
3. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
4. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of mucoadhesive PLGA microparticles for nasal immunization.
Pawar D; Goyal AK; Mangal S; Mishra N; Vaidya B; Tiwari S; Jain AK; Vyas SP
AAPS J; 2010 Jun; 12(2):130-7. PubMed ID: 20077052
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
Tafaghodi M; Saluja V; Kersten GF; Kraan H; Slütter B; Amorij JP; Jiskoot W
Vaccine; 2012 Aug; 30(36):5341-8. PubMed ID: 22749834
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
9. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
Mangal S; Pawar D; Garg NK; Jain AK; Vyas SP; Rao DS; Jaganathan KS
Vaccine; 2011 Jul; 29(31):4953-62. PubMed ID: 21575664
[TBL] [Abstract][Full Text] [Related]
11. Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan.
Li Z; Xiong F; He J; Dai X; Wang G
Eur J Pharm Biopharm; 2016 Dec; 109():24-34. PubMed ID: 27569030
[TBL] [Abstract][Full Text] [Related]
12. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
13. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
[TBL] [Abstract][Full Text] [Related]
14. Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B.
Mishra N; Tiwari S; Vaidya B; Agrawal GP; Vyas SP
J Drug Target; 2011 Jan; 19(1):67-78. PubMed ID: 20334603
[TBL] [Abstract][Full Text] [Related]
15. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.
Thomas C; Gupta V; Ahsan F
Int J Pharm; 2009 Sep; 379(1):41-50. PubMed ID: 19524654
[TBL] [Abstract][Full Text] [Related]
16. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
17. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
Shi L; Caulfield MJ; Chern RT; Wilson RA; Sanyal G; Volkin DB
J Pharm Sci; 2002 Apr; 91(4):1019-35. PubMed ID: 11948541
[TBL] [Abstract][Full Text] [Related]
19. Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens.
Alkie TN; Yitbarek A; Taha-Abdelaziz K; Astill J; Sharif S
PLoS One; 2018; 13(11):e0206324. PubMed ID: 30383798
[TBL] [Abstract][Full Text] [Related]
20. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine.
Thomas C; Rawat A; Hope-Weeks L; Ahsan F
Mol Pharm; 2011 Apr; 8(2):405-15. PubMed ID: 21189035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]